Literature DB >> 3109237

Infectious hepatitis in dialysis patients.

N Shusterman, I Singer.   

Abstract

Infectious hepatitis is a major problem for patients with end-stage renal disease and for staff caring for these patients. Initially hepatitis B was the major cause of hepatitis in dialysis patients and staff. Patients had a tendency to develop chronic hepatitis or become chronic carriers of the virus while staff either developed typical acute hepatitis or a primary antibody response. The discovery of the hepatitis B surface antigen (HBsAg), the screening of transfused blood for HBsAg, and the institution of infection control measures including isolation techniques have resulted in a remarkable decrease in the incidence of this disease. Nonetheless, the problem of infectious hepatitis continues as non-A, non-B hepatitis has become more commonplace among dialysis patients. Unfortunately, no viral markers have been discovered, and blood products remain the major vehicle of transmission. The institution of infection control measures similar to those used to control hepatitis B has probably been effective in controlling the spread of this disease. It is hoped that the discovery of the etiologic agent(s), with the eventual goal of screening blood products and the development of a vaccine, will lead to full control of this disorder.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109237     DOI: 10.1016/s0272-6386(87)80070-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Detection of antibodies to hepatitis C virus in dialysis patients.

Authors:  D Rivanera; D Lilli; G Lorino; V Pirozzi; V Cannulla; G Dicuonzo; C Mancini
Journal:  Eur J Epidemiol       Date:  1993-01       Impact factor: 8.082

2.  Prevalence of antibodies to hepatitis C virus among Omani patients with renal disease.

Authors:  S H al-Dhahry; P N Aghanashinikar; M K al-Hasani; M R Buhl; A S Daar
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

3.  A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.

Authors:  E Z Oddone; P A Cowper; J D Hamilton; J R Feussner
Journal:  Health Serv Res       Date:  1993-04       Impact factor: 3.402

4.  Vaccination against hepatitis B infection in patients with end stage renal disease.

Authors:  K Bel'eed; M Wright; D Eadington; M Farr; L Sellars
Journal:  Postgrad Med J       Date:  2002-09       Impact factor: 2.401

5.  Hepatitis C infection in hemodialysis units.

Authors:  S K Ha; J H Park; W C Choi; K H Kim; K H Choi; H Y Lee; D S Han; K S Song; H O Kim; S H Chung
Journal:  Korean J Intern Med       Date:  1990-07       Impact factor: 2.884

6.  Hepatitis B, delta and human immunodeficiency virus infections among Omani patients with renal diseases: A seroprevalence study.

Authors:  S S Al-Dhahry; P N Aghanashinikar; H A Al-Marhuby; M R Buhl; A S Daar; M K Al-Hasani
Journal:  Ann Saudi Med       Date:  1994-07       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.